Yatai Pharmaceutical swings to loss in 2026 interim report, net profit negative 435,500 yuan
Yatai Pharmaceutical released its 2026 interim report. Total operating revenue was 158 million yuan, and net profit attributable to the parent company was negative 435,500 yuan, swinging from profit to loss. Compared with the same period last year, it decreased by 106 million yuan, a year-on-year decline of 100.41 percent. Net cash inflow from operating activities was negative 68.2129 million yuan, a year-on-year decline of 344.52 percent. The company's asset-liability ratio was 5.71 percent, gross margin was 34.27 percent, ROE was negative 0.04 percent, and diluted earnings per share was negative 0.00 yuan. The number of shareholders was 68,000, and the top ten shareholders held 20.37 percent of total share capital.
002370.CS▼
Yatai Pharmaceutical posts net loss of 440,000 yuan in first half, down 100.4% year on year
Yatai Pharmaceutical released its 2026 interim report, showing a net loss attributable to the parent company of 440,000 yuan in the first half, down 100.4% year on year. Operating revenue was 158 million yuan, up 3.6% year on year. Net profit attributable to the parent company excluding non-recurring items was 1.4 million yuan, compared with a loss of 48.86 million yuan in the same period last year. Second-quarter net profit attributable to the parent company was 2.15 million yuan, down 98.1% year on year. As of the end of the second quarter, total assets stood at 1.192 billion yuan, down 6.9% from the end of the previous year.
Yatai Pharma Completes First Share Buyback of Approximately 3.34 Million Shares
Yatai Pharma has completed its first share buyback through centralized bidding, repurchasing approximately 3.34 million shares, representing 0.45% of the company's total share capital. The transaction price ranged from 5.91 yuan to 6.03 yuan per share, with a total transaction value of approximately 19.998 million yuan. The company previously announced a buyback plan with a total fund allocation of 10 million to 20 million yuan, at a price not exceeding 7 yuan per share, to be used for equity incentives or employee stock ownership plans.
002370.CS
Yatai Pharma Subsidiary Plans to Invest RMB 5 Million for a 7.69% Stake in an Investment Fund
Yatai Pharma's wholly-owned subsidiary, Zhejiang Yatai Lizhong Holdings, plans to invest RMB 5 million of its own funds to subscribe for expanded shares in the Qingdao Yanghe Cangqiong Venture Capital Fund Partnership, representing 7.69% of the total committed capital. The fund primarily invests in equity assets such as high-quality unlisted company shares in sectors like high-end manufacturing and non-publicly traded securities of listed companies. In the first quarter of 2026, Yatai Pharma recorded revenue of RMB 59.58 million and a net loss attributable to the parent company of RMB 2.59 million.
Yatai Pharmaceutical's Spironolactone Tablets Pass Generic Drug Consistency Evaluation
Yatai Pharmaceutical announced that it recently received the Drug Supplementary Application Approval Notice for Spironolactone Tablets issued by the National Medical Products Administration. The 25 mg strength of the drug has passed the generic drug quality and efficacy consistency evaluation. Spironolactone tablets are indicated for edematous conditions, hypertension, primary aldosteronism, and the prevention of hypokalemia. Passing this consistency evaluation will enrich the company's product pipeline, enhance market competitiveness, and accumulate experience for subsequent consistency evaluations of other products.
Yatai Pharma Plans to Buy Back Shares Worth 10 Million to 20 Million Yuan for Equity Incentives
Yatai Pharma announced that the company plans to use its own funds and self-raised funds to buy back some shares through centralized bidding. The total buyback amount will be no less than 10 million yuan and no more than 20 million yuan, with a buyback price not exceeding 7.00 yuan per share. Based on the upper limit of the buyback amount, it is estimated that about 2.86 million shares can be repurchased, accounting for approximately 0.38% of the company's total share capital. The repurchased shares will be used for equity incentives or employee stock ownership plans. The buyback period shall not exceed 12 months from the date of approval by the board of directors.
Yatai Pharma Chairman Proposes Share Buyback of 10 Million to 20 Million Yuan
Qiu Zhongxun, the actual controller, chairman, and general manager of Yatai Pharma, has proposed that the company use its own funds and/or self-raised funds to repurchase some shares for equity incentives or employee stock ownership plans. The total amount for this buyback is 10 million to 20 million yuan, and the implementation period will not exceed 12 months from the date the board of directors approves the plan.
002370.CS▲
Yatai Pharma Adds Five Products to National Essential Medicines List
Yatai Pharma announced that a total of 27 of its products have been included in the National Essential Medicines List 2026 edition, with five new additions and one removal. The newly added products are cefixime capsules, azithromycin for injection, acyclovir for injection, febuxostat tablets, and esomeprazole sodium for injection, while the removed product is clarithromycin capsules. The company expects this adjustment to have a positive impact on subsequent market expansion, driving broader coverage of the relevant products in the primary healthcare market and enhancing market competitiveness.
China